At the 2013 Annual Meeting for AABB, Quotient presented two posters of the first published results from our development program, MosaiQ. The first poster, which had been selected by AABB as a "Top Poster" and entitled "Evaluation of a Novel Serology-Based Platform for Irregular Blood Group Antibody Identification (MosaiQ)", presented data from a 1,000 sample study demonstrating the ability to identify irregular blood group antibodies using MosaiQ.
The second poster entitled "ABO and Rh Antigen Typing of Red Blood Cells Using a Novel Serology Based Multiplexed Protein Microarray Platform (MosaiQ)" presented data from a study using 1,022 samples demonstrated the feasibility of the MosaiQ platform as an antigen typing platform.
In both studies results were compared and correlated to column agglutination technology.
There will be several more scientific presentations on MosaiQ in the next few months.